Cargando…
Rivaroxaban Monotherapy for Atrial Fibrillation and Coronary Artery Disease in Underweight/Obese Patients: Evidence Is Needed
[Figure: see text]
Autores principales: | Zhou, Dao, Fan, Jiaqi, Liu, Xianbao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9877208/ https://www.ncbi.nlm.nih.gov/pubmed/36713757 http://dx.doi.org/10.1016/j.jacasi.2022.09.008 |
Ejemplares similares
-
Rivaroxaban Monotherapy in Atrial Fibrillation and Stable Coronary Artery Disease Across Body Mass Index Categories
por: Ishii, Masanobu, et al.
Publicado: (2022) -
Rivaroxaban in atrial fibrillation
por: Giorgi, Mariano A, et al.
Publicado: (2012) -
Rivaroxaban Monotherapy in Patients With Atrial Fibrillation and Coronary Stenting at Multiple Vessels or the Left Main Trunk: The AFIRE Trial Subanalysis
por: Ishii, Mitsuru, et al.
Publicado: (2022) -
Uncertainty on the effectiveness and safety of rivaroxaban in premenopausal women with atrial fibrillation: empirical evidence needed
por: Rolden, Herbert J. A., et al.
Publicado: (2017) -
Edoxaban Monotherapy in Nonvalvular Atrial Fibrillation Patients with Coronary Artery Disease
por: Fukamachi, Daisuke, et al.
Publicado: (2022)